Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

0GP7

Medivir Ab (0GP7)

Medivir Ab
De:
Trier par:
 Showing the most relevant articles for your search:LSE:0GP7
DateHeureSourceTitreSymboleSociété
15/01/202408h45PR Newswire (US)Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostroxLSE:0GP7Medivir Ab
04/01/202408h47PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyLSE:0GP7Medivir Ab
19/12/202308h54PR Newswire (US)Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development planLSE:0GP7Medivir Ab
13/12/202311h12PR Newswire (US)Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approvalLSE:0GP7Medivir Ab
06/12/202312h20PR Newswire (US)Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runwayLSE:0GP7Medivir Ab
06/12/202308h44PR Newswire (US)Medivir to present at the Carlsquare Equity Research Investor DayLSE:0GP7Medivir Ab
01/12/202311h32PR Newswire (US)Bulletin from Extraordinary General Meeting in Medivir AB (publ)LSE:0GP7Medivir Ab
27/11/202309h52PR Newswire (US)Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCCLSE:0GP7Medivir Ab
22/11/202308h46PR Newswire (US)Medivir to present at the Redeye Life Science DayLSE:0GP7Medivir Ab
21/11/202308h48PR Newswire (US)Medivir to present at the Erik Penser Bank Company EventLSE:0GP7Medivir Ab
13/11/202309h49PR Newswire (US)Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDALSE:0GP7Medivir Ab
07/11/202321h50PR Newswire (US)Notice of Extraordinary General Meeting in Medivir AB (publ)LSE:0GP7Medivir Ab
27/10/202309h01PR Newswire (US)MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023LSE:0GP7Medivir Ab
25/10/202308h46PR Newswire (US)Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on FridayLSE:0GP7Medivir Ab
23/10/202308h48PR Newswire (US)Nomination Committee of Medivir appointedLSE:0GP7Medivir Ab
20/10/202315h29PR Newswire (US)Change in Medivir's Board of DirectorsLSE:0GP7Medivir Ab
16/05/202318h38PR Newswire (US)Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023LSE:0GP7Medivir Ab
04/05/202316h55PR Newswire (US)Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)LSE:0GP7Medivir Ab
04/05/202316h25PR Newswire (US)Resolutions at the Annual General Meeting in Medivir on 4 May 2023LSE:0GP7Medivir Ab
27/04/202309h06PR Newswire (US)MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2023LSE:0GP7Medivir Ab
17/04/202309h30PR Newswire (US)Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combinationLSE:0GP7Medivir Ab
04/04/202311h03PR Newswire (US)Medivir 2022 Annual Report publishedLSE:0GP7Medivir Ab
31/03/202312h25PR Newswire (US)Notice of Annual General Meeting of Medivir AB (publ)LSE:0GP7Medivir Ab
17/03/202309h01PR Newswire (US)Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACRLSE:0GP7Medivir Ab
14/03/202309h18PR Newswire (US)First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®LSE:0GP7Medivir Ab
08/03/202316h08PR Newswire (US)Medivir to present at the Stockholm Corporate Finance Life Science DayLSE:0GP7Medivir Ab
23/02/202309h03PR Newswire (US)Medivir to present at the Erik Penser Bank Healthcare DayLSE:0GP7Medivir Ab
21/02/202309h54PR Newswire (US)Pia Baumann takes up her position as Chief Medical OfficerLSE:0GP7Medivir Ab
20/02/202311h04PR Newswire (US)Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCCLSE:0GP7Medivir Ab
15/02/202309h15PR Newswire (US)MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2022LSE:0GP7Medivir Ab
 Showing the most relevant articles for your search:LSE:0GP7

Dernières Valeurs Consultées

Delayed Upgrade Clock